BioCentury | May 12, 2014
Finance

A one-two punch

...population commonly found in hospitals or long-term care facilities. Naurex is a 2008 restart of Nyxis Neurotherapies Inc....
BioCentury | May 16, 2011
Finance

Naurex Nyxis the Past

...Naurex nyxis the past Naurex Inc. , a restart neurology play, has raised $18 million in...
...up front and up to $300 million in milestones. Naurex is a 2008 restart of Nyxis Neurotherapies Inc....
...is developing a second generation of GFPAs, many of which are orally available. Small said Nyxis...
BioCentury | May 12, 2011
Financial News

Naurex raises $18 million

...product is a glycine site functional partial agonist selective modulator of the NMDA receptor . Nyxis Neurotherapies Inc....
BioCentury | Sep 16, 2002
Product Development

NMDA outlook

...neuropathy; AIDS-related dementia Ph III (AD, diabetic neuropathy); Ph II (AIDS-related dementia) Merz, Forest, Lundbeck Nyxis...
BioCentury | Aug 5, 2002
Clinical News

NT-13: Started Phase I

...receptor Description: NMDA receptor modulator Indication: Treat neuropathic pain and cognitive enhancement Endpoint: Safety Status: Nyxis...
Items per page:
1 - 5 of 5
BioCentury | May 12, 2014
Finance

A one-two punch

...population commonly found in hospitals or long-term care facilities. Naurex is a 2008 restart of Nyxis Neurotherapies Inc....
BioCentury | May 16, 2011
Finance

Naurex Nyxis the Past

...Naurex nyxis the past Naurex Inc. , a restart neurology play, has raised $18 million in...
...up front and up to $300 million in milestones. Naurex is a 2008 restart of Nyxis Neurotherapies Inc....
...is developing a second generation of GFPAs, many of which are orally available. Small said Nyxis...
BioCentury | May 12, 2011
Financial News

Naurex raises $18 million

...product is a glycine site functional partial agonist selective modulator of the NMDA receptor . Nyxis Neurotherapies Inc....
BioCentury | Sep 16, 2002
Product Development

NMDA outlook

...neuropathy; AIDS-related dementia Ph III (AD, diabetic neuropathy); Ph II (AIDS-related dementia) Merz, Forest, Lundbeck Nyxis...
BioCentury | Aug 5, 2002
Clinical News

NT-13: Started Phase I

...receptor Description: NMDA receptor modulator Indication: Treat neuropathic pain and cognitive enhancement Endpoint: Safety Status: Nyxis...
Items per page:
1 - 5 of 5